LMY-920 for Treatment of Relapsed or Refractory Myeloma

NCT05546723 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma, Refractory
Multiple Myeloma in Relapse

Interventions

BIOLOGICAL: Autologous CAR-T cell therapy expressing the BAFF-ligand.

Sponsor

Luminary Therapeutics

Collaborators

[object Object]
[object Object]